Pre-clinical studies indicate that raloxifene has an antiproliferactive effect on estrogen receptor (ER)-positive breast tumors and on the proliferation of ER-positive breast cancer cell lines and significantly reduces the risk of ER-positive but not ER-negative breast cancer [22]. Here, ESR1 is linked to breast carcinoma.